News / Press Release

Applied Clinical Trials: When is it Time to Kill Your Drug?

Applied Clinical Trials / July 27, 2018

It can be hard for drug makers to pull the plug on a drug in development, even when all signs indicate they should – resulting in many drugs getting past the preclinical floodgates, only to fail. The mistake: Not having a clinical strategy from the get-go.

A smart, defined clinical strategy sets objective expectations at the beginning of a drug’s development for when and on what criteria development will be terminated. This forces drug developers to ask, “Why are we creating this drug in the first place?”

The answer—and the true drug development opportunity—lies in an understanding of the best available science and patient target(s) for the drug.

Before you take your drug to the point of no return, learn more about TD2’s insight from president and CEO, Stephen Gately, on how to be more strategic from the start in Applied Clinical Trials.

For more information, please contact
About Translational Drug Development (TD2)

TD2 is an oncology development organization that provides innovative services for oncology-focused companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncology diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2’s suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit www.TD2inc.com.

About TD2

TD2 is an oncology development organization that provides innovative services for oncology-focused companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncology diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2’s suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit www.TD2inc.com.

Contact
Tara Franks
602-358-8322
Get free tips, tools and resources by subscribing to the TD2 Newsletter: